Article info
PDFSection 5: Patient safety and quality assurance
5PSQ-156 Compliance of recommendations for the prevention of hepatitis B virus reactivation during daratumumab treatment
Citation
5PSQ-156 Compliance of recommendations for the prevention of hepatitis B virus reactivation during daratumumab treatment
Publication history
- First published March 14, 2021.
Online issue publication
March 15, 2021
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.